Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC
Update: 2025-10-30
Description
Visit https://www.peervoice.com/XKC860 to view the entire programme with slides. After completing “Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC”, participants will be able to: Evaluate novel data presented at ESMO 2025 related to the use of androgen receptor pathway inhibitors (ARPIs) in the management of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), including relevant efficacy and safety data, subgroup analyses, and real-world evidence; and Assess the potential implications of recently presented findings for the clinical care of individuals living with mHSPC or nmCRPC.
Comments 
In Channel







